Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

AstraZeneca PLC (LSE:AZN) Holds Firm in FTSE 100 After Nine-Month Beat, Twelve Positive Phase III Readouts and Reiterated Guidance

With aMarket Valuethat dominates the FTSE 100, moves in the stock have an outsized effect on the index.

Ankur Sharma | 10 November 2026

AstraZeneca (LSE:AZN) Rallies After Q3 Beat and $1.5 Billion Savings Plan: FTSE 100 Pharma Giant Teases Over $20 Billion in 2027 Readouts

The shares had jumped about 5% in pre-market trading on 30 October after the results, taking them toward their 200-day average for the first time since July from a level near 13,050p.

Ankur Sharma | 10 November 2026

ConvaTec Group Plc (LSE:CTEC) Trends as FTSE 100 Medtech Offers Defensive Growth in a Rotation-Heavy Market

The group also sits at the intersection of two themes investors are weighing: ageing populations that raiseDemandfor chronic care products, and hospital and payer pressure on pricing. How the shares respond to those forces helps explain why they trend whenever medtech sentiment shifts.

Ankur Sharma | 10 November 2026

GSK plc (LSE:GSK) Stays in FTSE 100 Spotlight as Vaccine Weakness Offsets Higher Third-Quarter Sales

AstraZeneca, the other large UK pharmaceutical stock, reported firm nine-month numbers on 30 October, which sets a contrast with GSK’s vaccine concerns.

Ankur Sharma | 10 November 2026

GSK (LSE:GSK) Slips on Vaccine Weakness Despite Q3 Beat: FTSE 100 Drugmaker Awaits a Key FDA Decision on Nuvalent's Lung Cancer Drug

The shares had come under pressure after the third-quarter report on 28 October because of declining vaccine sales, even though the quarter beat forecasts and guidance was reaffirmed.

Ankur Sharma | 10 November 2026

Haleon PLC (LSE:HLN) Slides Among FTSE 100 Fallers as Sensodyne Maker Struggles to Shake Off Its Growth Reset

The shares are still absorbing the late-October trading disclosure, when the FTSE 100 constituent lost more than 12% in a single session. That update showed third-quarter revenue of £2.87 billion and organic growth of 2.6%, below the 3.2% the market had expected. Pricing added …

Ankur Sharma | 10 November 2026

EDX Medical Group PLC in Focus: EDX Medical’s insider signal Puts the FTSE AIM All-Share Story Under Review (LSE:EDX)

• The company’s activity is linked to develops and supplies diagnostic products and services intended to support earlier detection and treatment of disease.

Ankur Sharma | 10 November 2026

Ondine Biomedical Inc. in Focus: Ondine’s hospital-adoption test Puts the FTSE AIM All-Share Story Under Review (LSE:OBI)

• The company’s activity is linked to develops light-activated antimicrobial therapies designed to reduce infections and support infection prevention.

Ankur Sharma | 10 November 2026

Proteome Sciences plc in Focus: Proteome Sciences’ route to repeat revenue Puts the FTSE AIM All-Share Story Under Review (LSE:PRM)

• The company’s activity is linked to proteomics and biomarker services supporting pharmaceutical research, clinical development and precision medicine.

Ankur Sharma | 10 November 2026

Surgical Innovations Group plc in Focus: Surgical Innovations’ recovery signal Puts the FTSE AIM All-Share Story Under Review (LSE:SUN)

• The company’s activity is linked to design, manufacture and sale of minimally invasive surgical instruments, alongside original-equipmentManufacturingand precision engineering work.

Ankur Sharma | 10 November 2026
Support

Hi! How can we help you today?

Loading…